Welcome to our dedicated page for Ib Acquisition SEC filings (Ticker: IBAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for IB Acquisition Corp. (NASDAQ: IBAC) provides access to the company’s official regulatory disclosures as a blank check shell company in the Financial Services sector. These filings document how IB Acquisition Corp. structures its trust account, manages its timeline for completing an initial business combination, and records stockholder actions related to extensions and redemptions.
Among the important documents are current reports on Form 8-K, which describe material events such as the company’s entry into Amendment No. 1 to its Investment Management Trust Agreement and the adoption of a First Amendment to its Amended and Restated Articles of Incorporation. These filings explain how the deadline to consummate an initial business combination was extended, the conditions under which the trust account may be liquidated, and the circumstances in which funds in the trust account may be released, other than interest used to pay franchise and income taxes.
Filings also detail stockholder voting results at special meetings, including approval of extension proposals, trust amendment proposals, and adjournment proposals. They report how many shares were redeemed for cash from the trust account and the remaining balance subject to adjustments for tax withdrawals. Exhibits attached to these filings, such as the text of the First Amendment to the Amended and Restated Articles of Incorporation and Amendment No. 1 to the Investment Management Trust Agreement, provide the full legal language governing these changes.
On this page, users can review IB Acquisition Corp.’s SEC reports to understand its governance framework, the mechanics of its trust account, and the protections and redemption rights available to public stockholders. Real-time updates from the EDGAR system and AI-powered summaries help explain the implications of complex documents like 8-Ks and charter amendments, making it easier to interpret how each filing affects the company’s progress toward an initial business combination.
IB Acquisition Corp. obtained stockholder approval to extend the deadline to complete its initial business combination from March 28, 2026 to September 28, 2026 through amendments to its trust agreement and articles of incorporation. If no deal is completed by September 28, 2026, the trust account will be liquidated under specified redemption and liquidation procedures, with no trust amounts used to pay dissolution expenses. The changes also clarify that trust funds generally remain locked except for interest used to pay franchise and income taxes, and reinforce public stockholders’ rights to redeem their shares in connection with key charter amendments affecting redemptions or the business combination timeline.
IB Acquisition Corp. reported the results of a special stockholder meeting and related redemptions of its common stock. Stockholders owning 5,077,821 shares, or about 88.46% of shares outstanding as of the February 11, 2026 record date, were present or represented by proxy.
Each proposal voted on at the meeting received 5,007,821 votes for and 70,000 against, with no abstentions or broker non-votes, so all proposals were approved. Separately, holders of 731,741 shares chose to redeem their shares for cash at approximately $10.78 per share from the company’s trust account.
These redemptions will remove about $7.9 million from the trust account, leaving approximately $8.2 million remaining. The remaining trust balance may change to reflect tax withdrawals.
AQR-affiliated investment funds reported open-market sales of IB Acquisition Corp. common stock. On March 23, 2026, entities managed by AQR Capital Management sold a combined 335,000 shares of common stock at $10.80 per share.
The transactions were executed across multiple vehicles, including AQR Global Alternative Investment Offshore Fund, L.P., which held 143,785 shares after its sale, and other funds such as AQR Diversified Arbitrage Fund and several AQR arbitrage and UCITS funds. The sales are reported by AQR Capital Management Holdings, LLC, AQR Capital Management, LLC, and AQR Arbitrage LLC as indirect holdings of ten percent owners.
AQR-related investment entities reported an open-market sale of IB Acquisition Corp. common stock. An account identified as AQR DELTA Master Account, L.P. sold 4,619 shares of common stock on 2026-03-20 at $10.75 per share in an indirect transaction. After this sale, that indirect account held 0 shares of IB Acquisition Corp.
IB Acquisition Corp. reported that GNQ Insilico Inc. entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company on March 13, 2026 to collaborate on sales, marketing, development and alliance activities advancing AI-driven drug discovery and precision medicine solutions.
The collaboration has a global territory, an initial term of two years and is non-exclusive. The parties will jointly market combined solutions that integrate GNQ’s AI platforms with the Strategic Partner’s consulting, cloud, and quantum computing capabilities. This Form 8-K also states that IB Acquisition intends to file a Form S-4 registration statement and a proxy statement/prospectus in connection with the proposed business combination with GNQ.
IB Acquisition Corp. reports that its prospective merger partner, GNQ Insilico Inc., has entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company. The two-year, non-exclusive collaboration will jointly market AI-driven drug discovery and precision medicine solutions worldwide, combining GNQ’s proprietary AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
The report also reiterates a proposed business combination between IB Acquisition and GNQ. IB Acquisition plans to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus that will be sent to its stockholders in connection with the transaction.
IB Acquisition Corp. entered into a Business Combination Agreement to acquire GNQ Insilico Inc. by way of a statutory plan of arrangement under Canadian law. The Arrangement Consideration is stated as $500,000,000 plus any Revenue or Share Price Earnouts, with exchange mechanics tying issuance to a Company Exchange Ratio.
The transaction is subject to customary closing conditions including SPAC stockholder approval, court orders in Ontario, regulatory approvals, effectiveness of a Form S-4 registration statement, Nasdaq/NYSE listing approval, minimum net tangible assets of $5,000,001 at closing after redemptions and a possible PIPE, and other conditions. A $10,000,000 break-up fee applies for certain fraudulent or willful breaches. A concurrent Bridge Financing of up to $2,000,000 was arranged, with an initial $250,000 secured convertible note and five-year warrants.
IB Acquisition Corp. has entered a definitive business combination agreement to acquire GNQ Insilico Inc., valuing GNQ at US$500,000,000 plus potential revenue and share price earnouts. GNQ will become a Nasdaq-listed AI- and quantum-driven drug development company following a plan of arrangement under Canadian law.
The transaction is expected to provide approximately US$15 million of proceeds to GNQ through cash in IB Acquisition’s trust account and a PIPE of up to US$10 million, alongside a separate bridge financing of up to US$2,000,000 in 10% secured convertible notes and warrants. Closing, targeted for the third quarter of 2026, is subject to shareholder approvals, court orders, regulatory clearances, a minimum of US$5,000,001 in IB Acquisition net tangible assets, and at least US$15.0 million of available cash.
IB Acquisition Corp. is asking stockholders to approve a six-month extension of the deadline to complete its initial business combination, pushing the cutoff to September 28, 2026. This requires support from at least 65% of all outstanding common shares.
Holders of public shares can redeem for cash in connection with the extension, at an amount based on the cash in the trust account, which was about $16.1 million as of the record date. The company estimates this would be roughly $10.76 per public share. If the extension fails, the SPAC expects to liquidate and return trust cash to public holders.
Stockholders will also vote on amending the trust agreement to align it with the new deadline, plus an adjournment proposal that would let the board postpone the meeting if turnout or support is insufficient. As of the February 11, 2026 record date, there were 5,739,970 common shares outstanding, and insiders and affiliates controlled about 63% of the vote.
IB Acquisition Corp. is asking stockholders to approve a six‑month extension of its deadline to complete an initial business combination from March 28, 2026 to September 28, 2026. This requires approval of an Extension Proposal, a related Trust Amendment, and an Adjournment Proposal.
The proxy explains that if the extension is not approved and no deal closes by March 28, 2026, the company will redeem all public shares and liquidate the SPAC. Public holders may redeem their shares in connection with the extension vote for cash equal to their portion of the trust.
As of the February 11, 2026 record date, there were 5,739,970 common shares outstanding and approximately $16.092 million in the trust account, implying an estimated redemption price of about $10.76 per share at the special meeting. Sponsor‑related holders own about 63% of the outstanding shares and favor the extension, but public redemptions could significantly reduce trust cash and may affect Nasdaq listing status.